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Glomerular hemodynamics and hormonal participation on cyclosporine
nephrotoxicity. The mechanism of cyclosporine A (CyA) nephrotoxicity
is unclear. In order to evaluate renal microcirculation seven euvolemic
Munich—Wistar (MW) rats were studied after acute CyA treatment (50
mg/kg, i.v.). Both total glomerular filtration rate (GFR, 0.96 0.04 vs.
0.47 0.07 mI/mm) and single nephron GFR (27.90 3.39 vs. 14.02
3.49 nI/mm) declined significantly (P < 0.001). It was observed an
increase in afferent (RA, t 188%) and efferent (RE, t 360%) arteriolar
resistances that caused a decrease on glomerular plasma flow rate (QA)
from 100.99 17.09 to 44.37 13.37 nI/mm (P < 0.001). Mean
glomerular capillary hydraulic pressure (P0c) increased from 45 I to
55 4 mm Hg (P < 0.05) and the glomerular ultrafiltration coefficient
(K1) decreased by 70% (0.096 0.030 to 0.031 0.010 nI/sec - mm Hg,
P < 0.05). Additionally, in order to study hormonal participation in this
nephrotoxicity, other three groups of MW rats were previously treated
with captopril (2 mg/kg, i.v.), verapamil (20 sg/kg/min, i.v.) or indo-
methacin (2 mg/kg, i.v.). Both captopril and verapamil minimized the
renal effects of CyA, with a decline of —25% instead of —50% on GFR
and RPF. Moreover, two groups of Brattleboro rats were studied.
Acute CyA administration in homozygote Brattleboro rats produced a
decline of only —22% and —31%, respectively, in GFR and renal plasma
flow (RPF), when compared with MW rats (P < 0.05). Similar results
were observed in heterozygote Brattleboro rats when compared with
MW rats, disclosing differences due to a different strain of rats.
According to these data, acute CyA administration caused a reduction
in SNGFR due to an increase on RA and RE with decreases on QA and
K1 values. These studies suggest that, at least, the renin—angiotensin
system and ADH may participate in this glomerular function impair-
ment. Furthermore, indomethacin did not alter the effect induced by
CyA, indicating that prostaglandins may be not an important factor in
these alterations. The protective action of verapamil may indicate a
potential use of Ca channel blockers in order to minimize CyA
nephrotoxicity.
Cyclosporine A (CyA) is a potent immunosuppressive drug
which has afforded benefit in transplantation and in the treat-
ment of several immune—mediated diseases [1—3]. However, a
number of side effects are observed, with nephrotoxicity being
the most common and important [4—6].
The impairment of glomerular filtration rate (GFR) and thus,
acute renal failure (ARF) observed with CyA, appears to be
related with renal hemodynamic alterations [7, 8]. The ARF is
reversible when the dosage of CyA is diminished or withdrawn
[6]. Moreover, no significant glomerular lesions have been
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found by light, immunofluorescence or electron microscopy [4,
91. It has been suggested that hormonal factors may participate
in this acute nephrotoxicity. Both activation of renin—angi-
otensin (RAS) and suppression of prostaglandin (PG) systems
have been observed [9—11].
Therefore, to study the renal microcirculation in response to
acute CyA infusion, Munich Wistar rats were submitted to
glomerular hemodynamic studies. Also, in order to evaluate
hormonal factors in CyA toxicity, additional experimental
groups were treated with an angiotensin 1-converting enzyme
inhibitor (captopril), prostaglandin synthesis inhibitor (indo-
methacin), and calcium channel blocker (verapamil). The final
experimental group involved acute administration of CyA to
Brattleboro rats, a genetic diabetes insipidus strain lacking
endogenous vasopressin (ADH).
Methods
Studies were performed on 45 adult male, Munich Wistar rats
weighing between 250 and 320 g during two experimental
periods, as follows: Group 1, control rats (N = 7). After the
initial study period, a second period was performed with the
cyclosporine—vehicle, cremophor (Sandoz, Basle, Switzer-
land), 0.4 to 0.6 ml, i.v. Group 2 was CyA group (N = 10)
treated with CyA, 50 mg/kg body wt i.v. in the second period
study. Group 3 (N = 8) rats were treated with captopril (SQ
14,225, E.R. Squibb and Sons, Princeton, New Jersey, USA), 2
mg/kg body wt per hour i.v. during both experimental periods.
In the second period, CyA (50 mg/kg i.v.) was simultaneously
administered. Group 4, the verapamil group (N = 7), was
treated with 20 sg/kg/min (Dl-verapamil, Knoll, USA) during
both experimental periods. Similarly to group 3, CyA was
administered in the second period. Group 5 was the indometh-
acm group (N = 7). A dose of 2 mg/kg i.v. was administered in
bolus, after canulation of jugular vein, 45 minutes before the
initial period, and then CyA (50 mg/kg i.v.) was given in the
second period.
The experiments were also performed on rats of the Brat-
tieboro strain (National Institutes of Health, Maryland, USA),
weighing between 200 to 310 g, to evaluate the role of ADH in
CyA nephrotoxicity. In this Group 6, seven Brattleboro
heterozygote rats served as control group. After the first period,
CyA (50 mg/kg body wt i.v.) was administered and after 30
minutes, the second period was performed. Group 7 had nine
Brattleboro homozygotes rats that received CyA in the same
manner as Group 6.
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Each rat was allowed free access to water and a standard rat
pellet diet until the morning of study. Rats were anesthetized
with mactin, 100 mg/kg i.p., and placed on a temperature—regul-
ated micropuncture table. Immediately after anesthesia was
induced the left femoral artery was catheterized with a PE-50
polyethylene tubing, and approximately 70 p1 of arterial blood
was collected for baseline hematocrit (Hct) determination. This
arterial catheter was used for subsequent periodic blood sam-
pling and estimation of mean femoral arterial—pressure (AP),
with an electronic transducer (model P23 Db, Stathan Instru-
ments Div., Gould Inc., Hato Rey, Puerto Rico) connected to a
direct—writing Gould Recorder (model 2200, Cleveland, Ohio,
USA), Polyethylene catheters were also inserted into the right
and left jugular veins for infusion of inulin, p-aminohippuric
acid (PAH), CyA vehicle, verapamil, indomethacin, captopril,
saline and isoncotic rat serum. An i.v. infusion of 7.5% inulin
and 2% PAH solution in 0.9% sodium chloride was then started
at a rate of 1.2 ml/hour. Following tracheostomy, rats were
prepared in routine fashion for micropuncture study [12—14].
After an initial equilibration period of 45 minutes, appropriate
measurements and collections needed to characterize glomeru-
lar dynamics and Kf were obtained in Group 3. Throughout the
period of surgical preparation and experimental studies, all rats
received a continuous i.v. infusion of isoncotic rat serum to
maintain circulating plasma volume at conscious (or euvolemic)
levels, since plasma volume of rats prepared for micropuncture
is reduced by approximately 20% relative to unanesthetized
animal [12]. The following protocol for maintaining the
euvolemic state was used. Soon after collection of the baseline
arterial blood sample, isoncotic rat serum was infused for 45
minutes at the rate of 7 to 10 mllkg/hr, followed by reduction in
infusion rate to 1.5 mi/kg/hr for the remainder of each experi-
ment to maintain the hematocrit value at the baseline level
measured immediately after induction of anesthesia [12, 15].
In Brattieboro rats during the experiments the animals were
given a continuous intravenous infusion of normal saline at a
mean rate of 4 ml/l00 g body wt/hr in homozygote rats in order
to replace the urinary losses. In heterozygote rats, saline was
infused for 45 minutes at the rate of 7 to 10 ml/kg/hr, followed
by reduction in infusion rate to 1.5 mi/kg/hr for the remainder of
each experiment. In both groups Hct were evaluated during the
experimental periods. A catheter (PE- 10) was also inserted into
the left ureter for urine sampling and flow rate determination.
Following these procedures the left kidney was exposed and
prepared for micropuncture study. After 30 to 45 minutes
equilibration the initial study period was begun. Two 15 minute
urine samples and blood samples of about 60 .d each were
collected for determinations Hct and total protein concentration
of inulin and PAH in plasma and urine. CyA was then admin-
istered and the same procedures were performed in the second
study period.
Micropuncture studies
In Group 3, initial micropuncture measurements were per-
formed in seven Munich Wistar rats. Exactly timed (1 to 3 mm)
samples of fluid were collected from surface proximal convolu-
tions of at least three nephrons for determinations of flow rate
and inulin concentration, and calculation of single—nephron
glomerular filtration rate (SNGFR). Coincident with these tu-
bule fluid collections, two or three samples of femoral arterial
blood were obtained in each period for determination of sys-
temic arterial Hct, total protein, inulin and PAH concentration
in plasma.
Hydraulic pressures were measured in single capillaries
within surface glomeruli by a continuous recording servonull
micropipette—transducer system (1PM mc, San Diego, Califor-
nia, USA). Micropipettes with outer tip diameters of 2 to 4 pm
and containing 2.0 M sodium chloride were used. Hydraulic
output from the servo-system was channeled via an electronic
transducer (Statham model P23Db) to a second channel of the
recorder. Direct measurements of hydraulic pressure in single
glomenilar capillaries (PGC), proximal tubules (PT), efferent
arterioles (PEA) and third—order peritubular capillaries (Pc)
were recorded in each rat.
To obtain estimates of colloid osmotic pressure (ir) of plasma
entering and leaving glomerular capillaries, we measured pro-
tein concentrations (C) in femorai arterial (CA) and efferent
arteriolar (CE) blood plasma as described previously [16]. CA
was taken as a measure of protein concentration in the afferent
arteriole. These estimates of pregiomerular and postglomerular
plasma protein concentrations permit calculation of colloid
osmotic pressures, single nephron filtration fraction (SNFF),
initial glomerular capillary plasma flow rate (QA), afferent (RA),
efferent (RE) and total (RT = RA + RE) arteriolar resistance and
glomerular capillary ultrafiltration coefficient (Kf), using equa-
tions given elsewhere [17].
Analytical procedures
The volume of tubule fluid collected was estimated from the
length of the fluid column in a constant—bore capillary tube of
known internal diameter. The concentration of inulin in the
tubule fluid was measured, usually in duplicate, by the
microfluorescence method of Vurek and Pegram [18]. Inulin
concentration in plasma and urine was determined by the
macroanthrone method of FUhr, Kaczmarczyk and Kruttgen
[19]. Protein concentrations in efferent arteriolar and femoral
arterial blood—plasmas were determined, usually in duplicate,
with an ultramicrocolorimeter by the method of Viets et al [16].
Glomerular filtration rate (GFR) was evaluated by inulin
clearances and renal plasma flow (RPF) by PAH clearances.
Plasma and urinary PAH concentrations were determined by
the method of Smith et al [20]. Total renal vascular resistance
(TRVR) was calculated as the AP/RPF ratio. Filtration fraction
(FF) was calculated as the quotient of GFR and RPF. Values of
GFR and RPF were corrected for kidney weight. Urinary Na
concentration was determined by flame photometry (Tecnow,
São Paulo, Brasil). Plasma protein levels were determined with
a refractometer and corrected on the basis of a standard curve
constructed by the method of Lowry, modified by Schachterle
[211.
Statistical analysis
Data were analyzed statistically by the Student unpaired and
paired two—tailed test. Statistical significance was taken as P <
0.05, all data were reported as means SEM.
Changes between the groups were statistically evaluated with
the Mann—Whitney test for unpaired and two tailed observa-
tion.
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Table 1. Summary of general data
Body wt Kg weight Hct0 Hct
Group g mm Hg %
CAO CA
gidi
1 304 iia 1.24 0.04 112 3 48 1 49 1 5.5 0.1 5.4 0.1
2 277 6 1.12 0.10 108 3 49 1 49 1 5.4 0.1 5.3 0.3
3 276±8 1.13±0.08 110±5 48±! 49±1 5.6±0.1 5.7±0.!
4 265 7 1.10 0.03 92 3" 48 1 48 1 5.6 0.3 5.7 0.3
5 265 6 1.16 0.03 114 3 49 1 56 1 5.5 0.1 5.7 0.1
6 276 5 0.86 0.03" 125 1 47 1 50 1 5.5 0.1 4.9 0.1
7 250 11 0.75 006b 101 4 46 1 45 1 5.6 0.1 4.3 0.1
Subscript o refers to baseline values at start of anesthesia
ax SE
b P < 0.05 vs. groups
C CA vs. CA0
Table 2. Summary of several measures of whole kidney function
GFR RPF FF
TRVR
mmHgminI
mi/mm mi/mm % ml
Group I
Saline 1.00 0.06a 2.75 0.30 38 3 44 5
Vehicle 1.03 0.07 2.82 0.31 37 1 41 4
Group 2
Saline 0.96 0.04 2.91 0.19 34 2 39 3
CyA 0.47 0.07" 1.30 0.23" 38 2" 129 40"
Group 3
Captopril 1.05 0.05 3.06 0.22 35 3 38 3
Captopril + CyA 0.82 0.04 2.50 0.15C 33 2 41 3C
Group 4
Verapamil 0.92 0.06 2.91 0.29 33 3
Verapamil + CyA 0.65 0.06" 2.31 0.17C 29 2"
34 3
38 3C
Group 5
Indomethacin 1.03 0.07 3.27 0.31 32 2 38 5
Indomethacin + CyA 0.55 009b 1.49 0.26" 37 3 86 15"
SEMValues are expressed as the mean
"P < 0.05 before vs. after CyA
P < 0.05 second period of groups 3, 4 and 5 vs. group 2
Results
General
Mean values of general data obtained in rats given vehicle or
CyA (Groups 1 and 2); CyA after captopril, verapamil and
indomethacin (Groups 3 to 5) and in Brattleboro rats (Groups 6
and 7) are summarized in Table 1. All groups were similar in
mean values for body and kidney weights and AP. However, in
Brattleboro rats, mean kidney weight was significantly lower
than for Munich Wistar rats (P < 0.05). Also, during verapamil
administration, mean AP was significantly reduced (P < 0.02).
The reduction was slight and the values were maintained well
within renal autoregulation levels (Table 1). Mean values for
initial and experimental periods for arterial hematocrit (Hct0,
Hct) and plasma protein concentration (CAO, CA) are also
similar in all studied groups, but for Groups 6 and 7 a decline of
CA was observed (P < 0.05, Table 1). However, the protein
concentrations were maintained stable during all experimental
periods (Table 1). Table 2 summarizes several whole kidney
functions in Groups 1 to 5. Vehicle infusion, Group 1, did not
change TRVR. CyA treatment (Group 2) induced significant
declines in GFR, 0.96 0.04 vs. 0.47 0.07 ml/min (P <
0.005), and in RPF, 2.91 0.19 vs. 1.30 0.23 mi/mm (P <
0.005), with an increase in FF, 34 2 vs. 38 2 (P < 0.01),
respectively. Also, CyA infusion caused a marked rise in
TRVR, from 39 3 to 129 40 mm Hg . mm/mI (P < 0.025).
Although not shown, CyA (Group 2) induced declines on
urinary sodium excretion, UNaV, from 0.65 0.17 to 0.23
0.04 tEq/min (P < 0.025) and in potassium excretion, UKV,
from 1.04 0.06 to 0.33 0.06 pEq/min (P < 0.001), with
maintenance of urine flow rate, 3.23 0.55 vs. 3.10 0.27
dJmin (P < 0.20).
Micropuncture studies
The micropuncture data obtained in Group 2 before and after
CyA infusion are shown in Table 3. Mean SNGFR and QA were
reduced after CyA infusion, 27.90 3.39 to 14.02 3.49 nI/mm
(P < 0.02) and 100.99 17.09 to 44.37 13.37 nI/mm (P <
0.001), respectively. SNFF increased from 0.30 0.03 to 0.34
0.03, but these values did not reach statistical significance.
Since PGC increased from 45 1 to 55 4 mm Hg (P < 0.02),
and T did not change, zP increased (Table 3). Both PEA and Pc
were not affected by CyA (Table 3). RT rose significantly. This
increase was accounted for by the rise in both RA and RE, but
mainly RE (P <0.05) as shown in Table 3.
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Table 3. Glomerular hemodynamic measurements before and after cyclosporine (CyA) administration in Group 2 rats
SNGFR QA SNFF
%
PGC PT zl' PEA 'C
n//,njn mm Hg
Before 27,90a
3.39
100.99
17.09
0.30
0.03
45
I
14
3
30
2
14
2
8
1
After 1402b
3.49
4437b
13.37
0.34
0,03
55
4
14
3
41b
3
14
2
9
2
a X SE
b P < 0.05 before vs. after CyA
Mean values for CA and thus ITA were similar before and after
CyA administration. However, CE and thus rE increased but
without significance (P <0.05) from 7.83 0.18 to 8.27 0.39
gIdl and 30.88 1,12 to 33.81 2.54 mm Hg (P < 0.10),
respectively. This increase was responsible for the slight in-
crease in SNFF. This increase was in similar proportion
(—'10%) as seen in whole kidney FF.
—
Since filtration pressure disequilibrium is defined as E/zP <
0.95 [131, in the period before CyA administration this condition
was obtained in four of seven rats. However, despite the
euvolemic condition, after CyA treatment, filtration pressure
equilibrium was obtained in five of seven rats. When the data
were analyzed statiscally (equilibrium or desiquilibrium), an
important declined on Kf of '—70% was observed (Table 3).
Effects of the angiotensin I-converting enzyme inhibitor,
captopril
Whole kidney GFR and RPF declined after CyA treatment
during captopril infusion (Table 2), from 1.05 0.05 to 0.82
0.04 mI/mm (P < 0.005) and from 3.06 0.22 to 2.50 0.15
mllmin (P < 0.005), respectively. These effects of CyA in this
group were reduced when compared with CyA treatment alone
(P < 0.001). Moreover, the effects of CyA on TRVR were
blunted by captopril infusion, 38 3 vs. 41 3 mm Hg . mm/mi
(P < 0.05), Table 2.
Effects of the Ca channel blocker, verapamil
Similar to captopril treatment, verapamil administration less-
ened the decline on GFR by CyA by -'-30%, from 0.92 0.06 to
0.65 0.06 mI/mm (P < 0.001). The changes in RPF and RVR
induced by CyA were also blunted by verapamil (Table 2).
Effects of prostaglandin inhibitor, indomethacin
Different from the observed results with captopril and
verapamil, indomethacin failed to modify the renal alterations
induced by CyA. GFR and RPF declined to the same extent
after CyA in the presence or absence of PG inhibition. Also,
TRVR increased despite the presence of indomethacin.
Effects of CyA in Brattleboro rats
The infusion of CyA in Brattleboro heterozygote rats (Group
6) led to marked falls in GFR and RPF, from 0.99 0.06 to 0.42
0.06 (P < 0.01) and from 2.67 0.26 to 0.94 0.12 (P <
0.01), respectively (Table 4). Total RVR increased from 51 4
to 147 21, (Table 3). The changes in these parameters were
similar to those seen in Munich Wistar rats, indicating no
differences in the overall nephrotoxic susceptibility to CyA
between both strains. The treatment of CyA in Brattleboro
homozygotes rats, however, did not alter renal function as
extensively as observed for Brattleboro heterozygotes or
Munich Wistar rats (Table 4). GFR and RPF declined from 0.88
0.04 to 0.69 0.06 mI/mm (P < 0.05) and from 2.76 0.20 to
1.91 0.13 mllmin (P < 0.05), respectively. Again, both values
were significantly less affected than observed for CyA in
heterozygotes and Munich Wistar rats (P < 0.05). Total RVR
increased but to a lesser extent than for Group 6 (P < 0.05).
Discussion
CyA has become a commonly—employed immunosupressive
drug for cardiac, hepatic, renal and other organ transplantation
[3, 22]. It has been demonstrated that patient and allograft
survival is enhanced by its use [2]. Moreover, an increased
number of immune mediated diseases are now being treated
with CyA [3, 23]. However, several adverse effects limit its use,
nephrotoxicity being one of the most important of them [5]. In
humans, the nephrotoxicity is mainly characterized by diffuse
interstitial fibrosis, arteriolopathy and tubulopathy [4, 5, 24].
No significant glomerular lesions are found. However, acute
tubular necrosis is the most restrictive alteration for the use of
CyA [25]. Myers et al [22] observed in patients with cardiac
transplantation that the chronic use of CyA produced a reduc-
tion in renal plasma flow associated with a variable degree of
tubulo-interstitial injury. These lesions were accompanied by
focal glomerular sclerosis. Similar functional and morphological
alterations were found in rat, but less pronounced [24]. In
addition, doses of 50 to 100 mg/kg in rats precipitate ARF
caused by proximal tubular damage [25]. Also, acute and
chronic administration of CyA alters glomerular hemodynamics
[7, 8]. A significant fall in total RPF together with a marked rise
in TRVR were the major reported findings [7].
In the present study, acute CyA administration caused an
important fall in GFR. This fall was caused by a marked
increase in TRVR which in turn determined a prominent
decrease in RPF. Therefore, whole kidney hemodynamics
suggest an increase of renal vascular resistance, predominantly
postglomerular since FF also regularly increases.
Moreover, acute administration of CyA in euvolemic rats
leads to a marked decrease in urinary sodium and potassium
excretion (P < 0.05). We found an important decrease in
fractional and absolute potassium excretion. The decreased
potassium excretion was probably determined by a reduction
on distal delivery of sodium. These data are also observed by
Tonnesen, Hammer and Weinmann [26] that found a decrease
in fractional and absolute sodium and potassium excretion with
CyA.
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Table 3. Continued
RA RE RT CA
gidI
CF A E
mm Hg i3P
Kf
nII(sec mm Hg)X1O'° dyn sec cm5
Before 2.9Y'
0.42
1.48 4.39
0.29 0.64
5.41
0.16
7.83
0.18
17.82
1.01
30.88
1.12
1.04
0.08
0.096
0.030
After 8.38
3.75
682b 1521b
2.04 5.61
5.43
0.17
8.27
0.39
17.55
0.81
33.81
2.54
084b
0.06
0031b
0.010
To clarify the pathophysiological mechanism(s) of acute renal
failure induced by CyA, glomerular hemodynamic studies were
performed in euvolemic Munich—Wistar rats. We observed a
marked increase in both afferent and efferent arteriolar resis-
tances; the greater increment in efferent arteriolar resistance
determined a significant increase on P0c. Since PT remained
unaltered it is possible to conclude that in CyA nephrotoxicity,
not only can tubular obstruction be excluded but also that a
significant increase in mean P occurs. Moreover since mean
Pc and mean PAE were maintained at values similar to control,
an important increase on interstitial pressure could be ex-
cluded.
Despite the observed increase in mean P (P = GC — PT),
augmented values for SNGFR were not found. Actually,
SNGFR was reduced. The arteriolar vasoconstriction deter-
mined a fall on mean QA. Nevertheless, the fall on QA was not
the only factor responsible for the decline in SNGFR. Our data
indicate that SNGFR was also decreased due to a significant fall
in Kf. The decline on Kf was also suggested in man by Myers et
al [22] who observed a 36% reduction of glomerular membrane
pore density in patients after heart transplantation [22, 27].
Moreover, they also deduced by indirect methodology an
increase in P, similar to that observed by direct micropuncture
data in rats in the present paper. These findings in glomerular
hemodynamics all taken together resemble those produced by
endogenous or exogenous angiotensin II [13, 28]. In fact,
angiotensin II is capable to produce glomerular mesangial cell
contraction and has an effect of reducing K [13, 29]. Moreover,
it has been suggested that renal functional changes induced by
CyA on total renal blood flow and glomerular filtration rate
observed in rats may be caused by stimulation of the
renin—angiotensin system [9, 11]. Actually, CyA has been
shown to stimulate the renin—angiotensin system both in vitro
and in vivo [9, 11, 30, 31]. In in vivo experiments, with
spontaneous hypertensive rats (SHR), Siegel et al [11] induced
acute renal failure and renin—angiotensin system activation with
CyA administration. In vitro, Baxter et al [30] have shown
stimulation of renin release from rat renal cortical slices by
CyA. In the present study in rats treated with captopril, we
observed that the renal vasoconstriction induced by CyA was
completely abolished (Table 2), the fall in GFR and RPF being
largely prevented. These findings suggest that angiotensin II
may play important role in the pathogenesis of renal vasocon-
striction produced by CyA. Angiotensin II could have altered
renal function in this model of nephrotoxicity by several mech-
anisms. One of them was through a stimulation of tubulo-
glomerular feedback mechanism, leading to an increase in renin
and angiotensin II production [11, 32]. Another possibility
Table 4. Summary of several measures of whole kidney function in
Brattleboro rats before and after CyA administration
TRVR
mm
GFR
mi/mm
RPF
mi/mm FF %
Hg . mini
ml
Homozygotes, N = 9
Before 0.88a 2.76
0.20
33 38
After 069b 191b
0.13
38 55b
Heterozygotes, N = 7
Before 0.99 2.67
0.26
38 51
After 042b 094b
0.12
45b 147b
a j SE
b P < 0,05 after vs. before CyA
could have been the direct action of angiotensin II in decreasing
Kf [13]. The benefical effects of captopril in rats receiving CyA
infusion could also be due to a stimulation of kallikrein—kinin
and/or on prostaglandin systems [33]. On the other hand,
Murray, Paller and Ferris (7) found no effect of captopril on
CyA induced fall in RPF despite the fact that an increase on
plasma renin activity was also observed. The relationship
between the stimulation of the renin—angiotensin system and
the observed functional abnormalities is not clear. Gerkens et al
[34] showed that high salt intake protects from CyA nephrotox-
icity while a low Na intake increases it. The stimulation of renin
by CyA may increase renal prostaglandin and thereby modulate
CyA nephrotoxicity. However, several studies have suggested
that renal PGs are depressed by CyA [10, 11, 35]. A decrease in
prostacyclin synthesis factor (PSF) has been described in CyA
treated rabbits [10]. In rats receiving CyA, prostacyclin (PGI2)
has been shown to be decreased in both rat skin allografts and
activated macrophages [36]. However, Paller and Murray [27]
observed that CyA administration is associated with a stimula-
tion of renal prostaglandin synthesis, resulting in increased
PGI2 urinary excretion. Inhibition of prostaglandin synthesis by
indomethacin or meclofenamate led to an increase in CyA renal
toxicity [7, 27]. In addition, Baxter et al [37] have suggested that
renal cortical concentration of PGE2, PGF2, 6-keto-PGF1 and
TXB2 are not different from normal levels in rats receiving
either acute or chronic doses of CyA. Recently it was suggested
that PGs affect CyA toxicity by blocking intestinal absorption of
this drug [38]. Thus, the conflicting and inconclusive studies did
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not permit a definitive statement to be made concerning the role
of prostaglandin on CyA nephrotoxicity. But, in the present
experimental model, the use of indomethacin maintained essen-
tially the same results as found with CyA alone, implying that
the prostaglandin system has a minor if any effect in impairing
glomerular hemodynamics during acute CyA treatment. It is
possible that CyA has a PG inhibition—like effect and thus,
simultaneous treatment with indomethacin and CyA did not
enhance the nephrotoxicity.
Since it is clear that CyA caused an increase in RVR, it
became important to evaluate the effect of a vasodilator Ca-
channel blocker drug. laina et al [39], observed that CyA plus
ischemia produces acute renal failure which can be attenuated
by the use of verapamil. Verapamil reduces the severity of renal
insufficiency as well as hystological damage. In the present
study, verapamil attenuated CyA effects on RVR and RPF
leading to an improvement in GFR. This protective action could
be explained either by arteriolar vasodilation and/or by inter-
action with the renin—angiotensin system, since calcium is a
final common pathway for both mechanisms [131.
Antidiuretic hormone (ADH) is another vasoactive substance
which is capable of influencing the process of glomerular
ultrafiltration, mainly by reducing Kf [13]. In the present study,
acute CyA administration in Brattleboro homozygote rats pro-
duced a decline of only 22% and 31%, respectively, in GFR and
RPF, when compared with the observed reductions of 51% and
55% (P < 0.05) seen in Munich Wistar rats. Perhaps, different
sensitivities of these rat strains to CyA could explain our
findings. To further elucidate this possibility, we performed the
same protocolol using heterozygote Brattleboro rats. In this
setting, results were not different from Munich Wistar rats,
denying therefore strain differences for CyA nephrotoxicity.
Therefore, we can postulate that the presence of ADH in some
way is necessary for that full nephrotoxic action of CyA to be
observed in the rat kidney. It is also clear that in the absence of
this hormone it is still possible to observe a significant nephro-
toxic action of this drug. It is possible that ADH participated in
this pathophysiology either by its vasoconstrictor effect or its
known action to reduce K1. The mechanism of the ADH-
associated fall in Kf is independent of a pathway involving
angiotensin II since it acts selectively on Kf, presumably via
mesangial cell contraction [13]. It is also possible that an
interelationship between anesthesia, ADH and renin secretion
could interfere with CyA nephrotoxicity. However, in Brat-
tleboro rats, the absence of ADH disclose the effect of anes-
thesia on ADH release and thus on renin secretion.
Finally, the influence of CyA on renal function in experimen-
tal animals is milder and, in order to produce a uniform
nephrotoxicity it was necessary to employ relatively high doses
[40]. Thus, in the present experimental protocol it is possible
that CyA causes an unique effect in the rat that may not occur
in man.
In summary, according to these data, acute CyA administra-
tion caused a reduction in single nephron filtration rate due to
an increase on afferent and efferent arteriolar resistance with a
decrease of QA and Kf values. These studies suggest that at
least the renin—angiotensin system and ADH may participate in
this glomerular function impairment. Furthermore, indometh-
acm did not alter the effect induce by CyA, indicating that PGs
may be not an important factor in these alterations. Finally, the
protective action of verapamil may indicate a potential use of
Ca channel blockers in order to minimize CyA nephrotoxicity.
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